Skip to main content
. Author manuscript; available in PMC: 2019 Aug 25.
Published in final edited form as: Nat Med. 2019 Feb 25;25(3):454–461. doi: 10.1038/s41591-019-0357-y

Extended Data Fig. 5. Clinical progression and neoantigen quantity and quality.

Extended Data Fig. 5

A, Disease-free survival of patients that recurred. B, CT image before and after of a patient with recurrent metastatic disease. C, Neoantigen load based on predicted binding (predicted kD of <500nM and mutant kD< WT kD). D, Number of high quality neoantigens that are likely to be recognized by TCR based on neoantigen fitness model33 at post treatment versus recurrence timepoints.